A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma
HD11
NCT05180097
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
|
Judit Kokai
438-888-1582
|
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
SGN35-015
NCT01716806
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
|
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
NCI-2022-10845 (AHOD2131)
NCT05675410
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
CHUL ET CENTRE MERE-ENFANT SOLEIL
|
|
Valerie-Eve Julien
418-525-4444
|
A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma
HD11
NCT05180097
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
|
Christine Lawson
819-346-1110 poste 12942
|
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
SGN35-015
NCT01716806
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Alessandra Figueiredo De Vasconcelos
514-340-8222 poste 26823
|
Groupe d'étude en oncologie du Québec